Estudo randomizado | Tirzepatida 1 vez/semana vs. insulina degludec 1 vez/dia em adição à metformina com ou sem inibidores de SGLT2 em pacientes com diabetes tipo 2.

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)

Conteúdos relacionados:

RCT: Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2.

RCT: Tirzepatide yielded greater glycated hemoglobin and body weight reductions compared to Semaglutide 1 mg.